{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:15:58Z","timestamp":1791825358630,"version":"4.3.4"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Effective antiviral therapy can significantly improve the long-term prognosis of HBV-related decompensated patients, and re-compensation may be achieved in part of the patients. To explore the re-compensation of ascites after HBV suppression and the risk factors, the clinical outcomes of 196 consecutive patients with HBV-related first decompensated cirrhosis of ascites treated with nucleos(t)ide analogue (NUC) were analyzed retrospectively. Among these patients, the median serum HBV DNA level was 5.0 (IQR, 3.0-6.0) log<jats:sub>10<\/jats:sub> IU\/mL before treatment. Most patients were given NUC with high barrier to resistance including ETV (152), TDF (1) and TAF (1). Initial combination of LAM plus ADV and LdT plus ADV was used in 41 patients and 1 patients, respectively. After NUC treatment, the percentage of patients with ascites regression was 77.6%, 81.4%, 70.5%, 93.8%, 80.8% at 12, 24, 36, 48, 60 months, respectively (P&amp;lt;0.001). The distribution of ascites severity showed that the patients\u2019 ascites improved, with the proportion of no ascites and mild ascites gradually increased. The proportion of re-compensation of ascites defined as negative HBV DNA, improved liver function and ascites regression (off diuretics) was 59.7%, 70.0%, 52.3%, 59.4%, 46.2% at 12, 24, 36, 48, 60 months (P&amp;lt;0.001). The rate of ascites regression was higher in viral response (VR) cohort when compared with that in non-VR cohort. Univariate and multivariable analysis showed that level of serum ALT (OR:0.988, 95%CI, p=0.029) and load of serum HBV DNA (OR:0.78895%CI, p=0.044) at baseline were risk factors of re-compensation of ascites. This study demonstrated that antiviral therapy could reverse decompensation of ascites in HBV-related first decompensated cirrhosis and the level of ALT and HBV DNA were risk factors of ascites re-compensation.<\/jats:p>","DOI":"10.3389\/fcimb.2022.1053608","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T06:19:21Z","timestamp":1673504361000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Ascites re-compensation in HBV-related first decompensated cirrhosis after anti-viral therapy"],"prefix":"10.3389","volume":"12","author":[{"given":"Mingyu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmiao","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisheng","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.jhep.2015.07.004","article-title":"Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis","volume":"63","author":"Bernardi","year":"2015","journal-title":"J. Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.jhep.2014.08.033","article-title":"Hepatitis b flares in chronic hepatitis b: pathogenesis, nsatural course, and management","volume":"61","author":"Chang","year":"2014","journal-title":"J. Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3390\/v14020434","article-title":"Current trend in antiviral therapy for chronic hepatitis b","volume":"14","author":"Chien","year":"2022","journal-title":"Viruses"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/liv.13129","article-title":"Incidence of hepatocellular carcinoma according to hepatitis b virus genotype in Alaska native people","volume":"36","author":"Ching","year":"2016","journal-title":"Liver Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jhep.2013.10.023","article-title":"The clinical course of cirrhosis. population based studies and the need of personalized medicine","volume":"60","author":"D'Amico","year":"2014","journal-title":"J. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2021.06.018","article-title":"Towards a new definition of decompensated cirrhosis","volume":"76","author":"D'Amico","year":"2022","journal-title":"J. Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D'Amico","year":"2006","journal-title":"J. Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - renewing consensus in portal hypertension","volume":"76","author":"De Franchis","year":"2022","journal-title":"J. Hepatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jhep.2018.08.009","article-title":"EASL clinical practice guidelines for the management of patients with decompensated cirrhosis","volume":"69","year":"2018","journal-title":"J. Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1055\/s-2003-37591","article-title":"Management of patients with decompensated HBV cirrhosis","volume":"23","author":"Fontana","year":"2003","journal-title":"Semin. Liver Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/hep.1840070124","article-title":"Compensated cirrhosis: natural history and prognostic factors","volume":"7","author":"Gin\u00e9s","year":"1987","journal-title":"Hepatology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12072-019-09933-8","article-title":"Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated","volume":"13","author":"Hanafy","year":"2019","journal-title":"Hepatol. Int."},{"key":"B13","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3760\/cma.j.issn.1007-3418.2019.12.002","article-title":"[Reversal of cirrhotic decompensation: re-compensation]","volume":"27","author":"He","year":"2019","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00365521.2022.2132532","article-title":"Two-year free of complications during antiviral therapy predicts stable re-compensation in immediate-treatment HBV-related decompensated cirrhosis","author":"He","year":"2022","journal-title":"Scand. J. Gastroenterol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1016\/j.cgh.2018.04.063","article-title":"Effects of virologic response to treatment on short- and long-term outcomes of patients with chronic hepatitis b virus infection and decompensated cirrhosis","volume":"16","author":"Jang","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14128","article-title":"How can we improve the performance of model for end-stage liver disease sodium score in patients with hepatitis b virus-related decompensated liver cirrhosis commencing antiviral treatment","volume":"13","author":"Kim","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/apt.16658","article-title":"Determinants of re-compensation in patients with hepatitis b virus-related decompensated cirrhosis starting antiviral therapy","volume":"55","author":"Kim","year":"2022","journal-title":"Aliment Pharmacol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"6278","DOI":"10.3748\/wjg.v19.i37.6278","article-title":"De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis b virus-related decompensated cirrhosis","volume":"19","author":"Lian","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.bpg.2017.04.010","article-title":"Natural history of acute and chronic hepatitis b: The role of HBV genotypes and mutants","volume":"31","author":"Lin","year":"2017","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.2471\/BLT.18.219469","article-title":"Countdown to 2030: eliminating hepatitis b disease, China","volume":"97","author":"Liu","year":"2019","journal-title":"Bull. World Health Organ"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.13828","article-title":"Gender differences in demographic and clinical characteristics in patients with HBV-related liver diseases in China","volume":"10","author":"Liu","year":"2022","journal-title":"PeerJ"},{"key":"B22","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis b: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1002\/hep.32065","article-title":"HBV genotype: A significant risk factor in determining which patients with chronic HBV infection should undergo surveillance for HCC: The hepatitis b Alaska study","volume":"74","author":"McMahon","year":"2021","journal-title":"Hepatology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00046-19","article-title":"Hepatitis b virus: Advances in prevention, diagnosis, and therapy","volume":"33","author":"Nguyen","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/jcph.181","article-title":"Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis b-associated decompensated cirrhosis: A meta-analysis","volume":"54","author":"Peng","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/infdis\/jiaa266","article-title":"Synergistic effect of biejia-ruangan on fibrosis regression in patients with chronic hepatitis b treated with entecavir: A multicenter, randomized, double-blind, placebo-controlled trial","volume":"225","author":"Rong","year":"2022","journal-title":"J. Infect. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/j.1365-2036.2011.04990.x","article-title":"Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis b virus cirrhosis","volume":"35","author":"Singal","year":"2012","journal-title":"Aliment Pharmacol. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis b: AASLD 2018 hepatitis b guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1097\/TP.0000000000001633","article-title":"Disease reversibility in patients with post-hepatitis c cirrhosis: Is the point of no return the same before and after liver transplantation? a review","volume":"101","author":"Vinaixa","year":"2017","journal-title":"Transplantation"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.jhep.2022.07.037","article-title":"Validation of baveno VII criteria for recompensation in entecavir-treated patients with hepatitis b-related decompensated cirrhosis","volume":"77","author":"Wang","year":"2022","journal-title":"J. Hepatol."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043083","article-title":"Recompensation factors for patients with decompensated cirrhosis: a multicentre retrospective case-control study","volume":"11","author":"Xu","year":"2021","journal-title":"BMJ Open"},{"key":"B32","doi-asserted-by":"publisher","first-page":"9609731","DOI":"10.1155\/2020\/9609731","article-title":"Recompensation of decompensated hepatitis b cirrhosis: Current status and challenges","volume":"2020","author":"Zhao","year":"2020","journal-title":"BioMed. Res. Int."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.1053608\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T06:19:24Z","timestamp":1673504364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.1053608\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":32,"alternative-id":["10.3389\/fcimb.2022.1053608"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2022.1053608","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,12]]},"article-number":"1053608"}}